Cloverfields Capital Group LP Buys 5,119 Shares of Novartis AG $NVS

Cloverfields Capital Group LP lifted its stake in shares of Novartis AG (NYSE:NVS) by 27.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,731 shares of the company’s stock after acquiring an additional 5,119 shares during the quarter. Cloverfields Capital Group LP’s holdings in Novartis were worth $3,272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NVS. Arlington Trust Co LLC acquired a new stake in Novartis during the 4th quarter valued at approximately $25,000. Bank of Jackson Hole Trust increased its position in Novartis by 425.0% during the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 187 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in Novartis during the 3rd quarter valued at approximately $33,000. South Plains Financial Inc. increased its position in Novartis by 39.0% during the 3rd quarter. South Plains Financial Inc. now owns 271 shares of the company’s stock valued at $35,000 after purchasing an additional 76 shares during the period. Finally, Aventura Private Wealth LLC acquired a new stake in Novartis during the 4th quarter valued at approximately $45,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on NVS shares. Morgan Stanley increased their price target on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. TD Cowen restated a “hold” rating on shares of Novartis in a report on Tuesday, February 17th. Weiss Ratings cut Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Sanford C. Bernstein upgraded Novartis to a “hold” rating in a report on Thursday, March 19th. Finally, Argus upgraded Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a report on Wednesday, March 11th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Novartis currently has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Trading Down 0.6%

Shares of Novartis stock opened at $153.03 on Friday. The stock has a fifty day simple moving average of $149.47 and a 200 day simple moving average of $148.06. Novartis AG has a 12-month low of $112.34 and a 12-month high of $170.46. The company has a market capitalization of $292.00 billion, a P/E ratio of 21.92, a price-to-earnings-growth ratio of 2.71 and a beta of 0.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The company had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. During the same quarter last year, the company posted $2.28 EPS. The company’s quarterly revenue was down .9% compared to the same quarter last year. On average, sell-side analysts anticipate that Novartis AG will post 8.83 earnings per share for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.